2,5-Dibromo-4-nitro-1H-imidazole
CAS: 6154-30-9
Rif. 3D-GAA15430
1g | Fuori produzione | ||
5g | Fuori produzione | ||
10g | Fuori produzione | ||
25g | Fuori produzione | ||
500mg | Fuori produzione |
Informazioni sul prodotto
- 1H-imidazole, 2,4-dibromo-5-nitro-
- 1H-Imidazole, 2,5-dibromo-4-nitro-
- 2,4-Dibromo-5-nitro-1H-imidazole
2,5-Dibromo-4-nitro-1H-imidazole (DBI) is a potential anti-tuberculosis drug that has been shown to have antimycobacterial activity in vitro. The drug targets the enzyme mycobacterial ATP synthase, which is involved in the synthesis of ATP and other nucleotides. DBI inhibits the growth of Mycobacterium tuberculosis and Mycobacterium bovis strains by binding to the benzyl group on the enzyme's active site. It also inhibits the growth of Mycobacterium smegmatis, a drug resistant strain of Mycobacterium tuberculosis. 2,5-Dibromo-4-nitro-1H-imidazole has been shown to bind to imidazole rings in M. tuberculosis and M. smegmatis without affecting their ability to grow or produce ATP.